why choose us

First received: November 23, 2022

Clinical Trial: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Primary Immune Thrombocytopenia (ITP)

Study Type: INTERVENTIONAL


Official Title: A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)

Brief Summary: The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ?30 G/L in adult participants with primary ITP.

Read more